Irinotecan liposomal and Pexidartinib Hydrochloride
Determining the interaction of Irinotecan liposomal and Pexidartinib Hydrochloride and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with pexidartinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of multidrug and toxin extrusion protein 1 (MATE1) and 2K (MATE2K) and organic anion transporting polypeptide (OATP) 1B1, 1B3, and 2B1. The proposed mechanism, based on in vitro data, is decreased clearance due to pexidartinib-mediated inhibition of these transport proteins. MANAGEMENT: Caution is advised if pexidartinib is used concomitantly with drugs that are substrates of MATE1, MATE2K, OATP1B1, OATP1B3, and OATP2B1, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever pexidartinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:MONITOR: Coadministration with pexidartinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of multidrug and toxin extrusion protein 1 (MATE1) and 2K (MATE2K) and organic anion transporting polypeptide (OATP) 1B1, 1B3, and 2B1. The proposed mechanism, based on in vitro data, is decreased clearance due to pexidartinib-mediated inhibition of these transport proteins.
MANAGEMENT: Caution is advised if pexidartinib is used concomitantly with drugs that are substrates of MATE1, MATE2K, OATP1B1, OATP1B3, and OATP2B1, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever pexidartinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: irinotecan liposomal
Brand name: Onivyde
Synonyms: Irinotecan (Liposomal)
Generic Name: pexidartinib
Brand name: Turalio
Synonyms: Pexidartinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Irinotecan liposomal-Pfizerpen
- Irinotecan liposomal-Pharaon Tea
- Irinotecan liposomal-Pharmorubicin Pfs
- Irinotecan liposomal-Phazyme
- Irinotecan liposomal-Phazyme Liquid Gas Relief, Maximum Strength
- Irinotecan liposomal-Phena-Plus
- Pexidartinib Hydrochloride-Irinotecan liposome Intravenous
- Pexidartinib Hydrochloride-Iron 100/C
- Pexidartinib Hydrochloride-Iron 21/7
- Pexidartinib Hydrochloride-Iron and Docusate
- Pexidartinib Hydrochloride-Iron and Folic Acid
- Pexidartinib Hydrochloride-Iron and Vitamin C